Antithrombotic drugs in cardiovascular medicine: a year in review
Review published in Current opinion in cardiology (2018)
Abstract
PURPOSE OF REVIEW: To provide an up to date review of the most recent randomized clinical trials in the field of antithrombotic drugs for cardiovascular diseases. RECENT FINDINGS: In 2017, low-dose anti-Xa treatment added to aspirin proved to be more efficacious than either treatment alone in patients with stable atherosclerotic disease despite the increase in nonfatal bleeding events. Furthermore, anticoagulation strategy during coronary interventions was again tested in a registry-based trial and showed comparable efficacy and safety between heparin alone and bivalirudin. Data from safety trials demonstrated lower risk of bleeding with dual antithrombotic therapy compared with triple antithrombotic therapy following coronary intervention, albeit these trials were underpowered for efficacy. Although still in its infancy, the role of antithrombotic treatment following transcatheter aortic valve replacement (TAVR) has been investigated in small trials with evidence that a single antiplatelet drug may be noninferior to dual antiplatelet therapy with a better safety profile. SUMMARY: In this review, we discuss the most recent clinical trials investigating antithrombotic drugs for cardiovascular diseases published in 2017.
Abstract sourced from PubMed (NCBI) for the cited record. See the original publication for the authoritative version.
Zusammenfassung
To provide an up to date review of the most recent randomized clinical trials in the field of antithrombotic drugs for cardiovascular diseases.
Warum dies für die Hirudotherapie relevant ist
This review summarizes 2017 randomized clinical trials of antithrombotic drugs in cardiovascular medicine, covering low-dose anti-Xa therapy added to aspirin, anticoagulation strategies during coronary interventions comparing heparin and bivalirudin, dual versus triple antithrombotic regimens after coronary intervention, and antithrombotic approaches following transcatheter aortic valve replacement. The abstract notes that bivalirudin showed comparable efficacy and safety to heparin alone in a registry-based trial during coronary interventions. The abstract does not mention hirudin, leeches, leech therapy, or the leech secretome, and names bivalirudin without characterizing its pharmacology or derivation. There is no defensible connection to hirudotherapy based on the abstract text.
Zitation
Antithrombotic drugs in cardiovascular medicine: a year in review
Ibrahim H et al. · Current opinion in cardiology, 2018
Verwandter klinischer Kontext
Erfahren Sie, wie diese Forschung mit der klinischen Praxis verknüpft ist
Zur ASH-Bibliothek hinzugefügt: May 27, 2026 · Letzte Aktualisierung der Website: June 18, 2026